Trial Profile

A Phase 1a/1b Open-Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of PY265 as a Single Agent and In Combination With Pembrolizumab in Subjects With Advanced Solid Tumors

Status: Not yet recruiting

Phase of Trial: Phase I

Latest Information Update: 27 Mar 2023

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

23 Mar 2023 According to a Pionyr Immunotherapeutics media release, the company will be ready to file an IND for PY265 in 2023.
24 Mar 2022 New trial record
22 Mar 2022 According to a Pionyr Immunotherapeutics media release, he company expect to initiate this study in 2023.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com